MBRX Moleculin Biotech Inc: Enterprise Value-to-Revenue Multiple

Moleculin (MBRX) - corporate logo

Moleculin Biotech, Inc. (MBRX) develops small molecules to combat aggressive cancers, leveraging its scientific authority. The GURU.Markets system calculates the EV-to-revenue ratio, where the 0.00 metric serves as the target level. Capital mobility is ensured by delegating research to international CROs, although a critical dependence on external synthetic partners and CMOs remains a key feature of the business model.

Moleculin Biotech - MBRX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

MBRX (Moleculin Biotech): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
- company stock capitalization data:
Initial company analysis:MBRX, Moleculin
Original product of moleculin.com

This indicator determines the market value of the business, adjusted for net debt, relative to annual revenue, allowing for an assessment of revenue capitalization efficiency without the influence of debt load. By analyzing the EV/Sales trend, an investor can evaluate the extent to which the market awards a premium to Moleculin Biotech (MBRX) for the implementation of robotic lipid nanoparticle synthesis, which radically accelerates the development of new drug formulas.